Gilteritinib
ATC L01EX13 · 9 markets · 11 records
GB 2 records · 1 strengths
- 40 mgtabletXospata__no_trade__
AU 2 records · 2 strengths
- 40 mgtabletXospata
Records without a stated strength · 1 Xospata
US 1 records · 1 strengths
- 40 mgtabletXospata
CA 1 records · 1 strengths
- 40 mgtabletXospata
CN 1 records · 1 strengths
- 40 mgtablet适加坦富马酸吉瑞替尼
ES 1 records · 1 strengths
- 40 mgtabletXospata
TW 1 records · 1 strengths
- 40 mgtabletXospata適加坦膜衣錠40毫克
HK 1 records · 1 strengths
Records without a stated strength · 1 Xospata
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 Xospata
| Strength / form / release | US | GB | CA | AU | CN | ES | TW | HK | EU |
|---|---|---|---|---|---|---|---|---|---|
| 40 mg tablet | Xospata | No trade name Xospata | Xospata | Xospata | 适加坦富马酸吉瑞替尼 | Xospata | Xospata 適加坦膜衣錠40毫克 | ||
unknown | Xospata | Xospata | Xospata |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.